Physician profile
Tom Middlebrook
NPI 1861599417
$27,660.27
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $3,773 · 2021: $333.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $27,037.87 | 2019-2021 | |
| Tris Pharma INC | $148.63 | 2019 | |
| Sunovion Pharmaceuticals INC. | $95.12 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $79.03 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $73.07 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.21 | 2019-2020 | |
| Neos Therapeutics, Lp | $32.65 | 2019 | |
| Supernus Pharmaceuticals, INC. | $32.16 | 2021 | |
| Shire North American Group INC | $30.79 | 2019 | |
| Corium, LLC | $23.20 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.09 | 2021 | |
| Neurocrine Biosciences, INC. | $21.06 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.95 | 2020 | |
| Adlon Therapeutics L.P. | $11.44 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Middlebrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.